Suggested Guidelines for Patient Monitoring: Hepatic and Hematologic Toxicity Attributable to Systemic Dermatologic Drugs

Stephen E. Wolverton, Kathleen Remlinger

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations

Abstract

Hepatic and hematologic toxicity are among the most fearful adverse effects that occasionally occur as a result of systemic drugs in the dermatologist's therapeutic armamentarium. Drugs of greatest interest concerning hepatic toxicity include methotrexate, azathioprine, dapsone, and acitretin. Somewhat overlapping are drugs that have important hematologic toxicities, including methotrexate, azathioprine, dapsone, sulfonamides, cyclophosphamide, and chlorambucil. Laboratory tests most commonly used include (1) hepatic monitoring: transaminases (AST/SGOT and ALT/SGPT) and the ultrasound-guided liver biopsy, and (2) hematologic monitoring: CBC with diff and platelets along with occasional use of the reticulocyte count. Important principles and specific guidelines for monitoring by drug group are highlighted.

Original languageEnglish (US)
Pages (from-to)195-205
Number of pages11
JournalDermatologic Clinics
Volume25
Issue number2
DOIs
StatePublished - Apr 1 2007

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Suggested Guidelines for Patient Monitoring: Hepatic and Hematologic Toxicity Attributable to Systemic Dermatologic Drugs'. Together they form a unique fingerprint.

Cite this